|
|
|
|
|
|
|
|
|
13.01.26 - 15:03
|
DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress (GlobeNewswire EN)
|
|
|
BROSSARD, Quebec, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in applying techniques in Artificial Intelligence (AI) for the early detection of eye-related health issues, is pleased to provide an update on the regulatory pathway for its AI platform, CARA. This follows the acceleration plan announced on October 8, 2025....
|
|
|
|
|
|
|
13.01.26 - 13:33
|
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient (GlobeNewswire EN)
|
|
|
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces the durable and sustained complete resolution of a lung metastasis in a patient with metastatic breast cancer (MBC) treated with Bria-OTS, BriaCell's personalized off the shelf immunotherapy. The patient is hormone receptor-positive (HR+), HER2-negative....
|
|
|
|
|
|
|
|
|
|
|
13.01.26 - 02:06
|
Rocket Doctor Announces Granting of RSUs and Options (GlobeNewswire EN)
|
|
|
Vancouver, BC, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc.'s (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) announces that the Company has granted an aggregate 75,000 stock options, exercisable at $0.74 per share and valid for a term of three years, and an aggregate 212,148 restricted share units, valid for a term of three years, to consultants of the Company. The stock options and restricted share units are issued pursuant to the Company's share compensation plans and are subject to vesting over one year....
|
|
|
|
|
|
|
|
|
12.01.26 - 14:33
|
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today outlined forward momentum across the Company's Phase 3 portfolio and discussed pipeline progress at the 2026 J.P. Morgan Healthcare Conference....
|
|
|
|
|
|
|
|
|
10.01.26 - 14:30
|
Thiogenesis-Aktie: Eine chancenreiche Wette (Sharedeals)
|
|
|
Die Thiogenesis-Aktie bleibt für Anleger eine spannende Wette, unabhängig von den Bewegungen an den Aktienmärkten. Diese Chancen bieten sich für potenzielle Investoren. Aktuelle Lage Aktuell bewegt sich die Aktie von Thiogenesis in einem Korridor von 0,50 CA$ und 0,90 CA$. Der Wert pendelt dabei, getrieben von Hype und fundamentalen Nachrichten. Zuletzt wurden positive Zwischenergebnisse im […]
The post Thiogenesis-Aktie: Eine chancenreiche Wette first appeared on sharedeals.de....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
